For more than a century, a name carried the weight of a misunderstanding—and 170 million women bore the consequences. The condition long called polycystic ovary syndrome has been renamed polyendocrine metabolic ovarian syndrome, or PMOS, following a decade of global research involving 22,000 people across six continents. The renaming, published in The Lancet, reflects a hard-won recognition that what was once framed as a gynecological problem is in fact a systemic hormonal and metabolic disorder—one that shapes a woman's health not just in her reproductive years, but across her entire life.
PCOS Renamed PMOS: A Game-Changing Recognition of Metabolic Disorder
170 million women worldwide experience delayed diagnosis (averaging 2+ years) and inadequate treatment due to misunderstanding of PMOS as primarily a gynecological rather than systemic metabolic disorder.
The name focused attention on the least of many patients' problems
Mark
Why does a name matter so much? The condition is the same whether it's called PCOS or PMOS.
Mimi
The name shapes what doctors look for and what they miss. When you call something "polycystic ovary syndrome," you're telling a doctor to focus on the ovaries. You're telling a patient her problem is about fertility or cysts. But the real problem is happening everywhere—in her hormones, her metabolism, her heart, her brain. The old name was a lie, even if nobody meant it to be.
Mark
So women were being treated for the wrong thing?
Mimi
Not entirely the wrong thing, but incompletely. A woman might be told to lose weight or see a fertility specialist, when what she actually needed was screening for diabetes, monitoring of her cardiovascular health, and recognition that this is a lifelong condition. The name change is saying: look at the whole person, not just the ovaries.
Mark
How long has this been a problem?
Mimi
The misunderstanding goes back to the 1950s, when the condition was first described. But it took 10 years of recent work—22,000 people across six continents—to build the case for change. That's how much evidence had to accumulate before the medical establishment would listen.
Mark
What changes for a woman who already has a PCOS diagnosis?
Mimi
Technically, nothing immediate. Her diagnosis becomes PMOS. She doesn't need new tests. But the hope is that her doctor will now understand her condition differently, and that future women will be diagnosed faster and treated more comprehensively. The real change is in how medicine thinks about her body.
Mark
Is there a cure on the horizon?
Mimi
Not yet. Treatment is still lifestyle first—diet, exercise, weight management—with medications to help. But a clearer understanding of what's actually happening might eventually lead to better treatments. For now, the name change is about seeing the problem clearly.
O Pulso
- The original name was built on a diagnostic error made in the mid-twentieth century, when immature egg follicles were mistaken for cysts—a mislabelling that quietly misdirected medical attention for decades.
- As a result, women with the condition faced an average diagnosis delay of more than two years, were rarely warned of their elevated risks for type 2 diabetes, cardiovascular disease, and depression, and were too often told their only concern was fertility.
- A consensus of 56 patient and professional organisations, spanning six continents and more than a decade of collaboration, has now formalised the new name PMOS to reflect the condition's true complexity across hormonal, metabolic, and ovarian systems.
- The diagnostic criteria remain unchanged—no new tests, no new appointments—but the shift in language is expected to accelerate diagnosis, prompt earlier metabolic screening, and reframe the condition as a lifelong health concern rather than a reproductive one.
For more than a century, a name carried the weight of a misunderstanding—and 170 million women bore the consequences. The condition long called polycystic ovary syndrome has been renamed polyendocrine metabolic ovarian syndrome, or PMOS, following a decade of global research involving 22,000 people across six continents. The renaming, published in The Lancet, reflects a hard-won recognition that what was once framed as a gynecological problem is in fact a systemic hormonal and metabolic disorder—one that shapes a woman's health not just in her reproductive years, but across her entire life.
A condition affecting an estimated 170 million women worldwide has been given a new name—one researchers hope will finally correct the misunderstanding that has defined the experience of living with it. Polycystic ovary syndrome, or PCOS, is now polyendocrine metabolic ovarian syndrome, PMOS. The change was published in The Lancet, the result of more than a decade of work involving 22,000 people and 56 organisations across six continents.
The old name was born from a mistake. When physicians first examined affected ovaries in the mid-twentieth century, they saw small fluid-filled structures and called them cysts. But those structures were never cysts—they were immature egg follicles that had stalled in development. Many women diagnosed with PCOS don't even have these ovarian abnormalities. The name pointed doctors and patients toward the wrong part of the body and the wrong understanding of what was happening.
In reality, PMOS is a systemic disorder. Male hormone levels are often elevated. The brain's signalling to the ovaries goes awry. Insulin resistance is common, which is why those with PMOS face significantly higher risks of type 2 diabetes, cardiovascular disease, fatty liver disease, depression, anxiety, and endometrial cancer. The condition begins early in life and persists throughout it. The new name tries to capture this: 'polyendocrine' for the multiple hormonal systems involved, 'metabolic' for the lifelong risks, 'ovarian' to retain the link to fertility and ovulation.
The practical cost of the old name has been considerable. Women were routinely told their symptoms were a fertility or weight problem. Diagnosis took, on average, more than two years. Few were warned about lifelong metabolic risks. The renaming should change this—prompting earlier screening, faster diagnosis, and a broader understanding that the condition does not end when a woman decides she no longer wants children.
The diagnostic criteria have not changed. An existing PCOS diagnosis simply becomes PMOS. No new tests are required. Treatment still begins with lifestyle change, supported where needed by metformin, hormonal contraceptives, or GLP-1 receptor agonists. But for the researchers who spent more than a decade on this effort, getting the name right is foundational—because a name shapes how doctors think, how patients understand their own bodies, and what kind of help they will seek and receive.
A condition that affects an estimated 170 million women worldwide has just been given a new name—one that doctors hope will finally stop the misdiagnosis and delay that has defined the experience of living with it. Polycystic ovary syndrome, known as PCOS, is now polyendocrine metabolic ovarian syndrome, or PMOS. The change arrived in a consensus paper published in The Lancet, the result of more than a decade of collaboration between researchers and patients across six continents, involving 22,000 people and 56 patient and professional organizations.
The old name was born from a mistake. When physicians first examined the ovaries of affected women under a microscope in the mid-twentieth century, they saw clusters of small, fluid-filled structures and called them cysts. The label stuck. But those structures were never actually cysts at all—they were immature egg follicles that had stalled in their development. Many women diagnosed with PCOS don't even have these ovarian abnormalities. The name, in other words, pointed doctors and patients toward the wrong part of the body and the wrong understanding of what was happening.
Dr. Elisabet Stener-Victorin, a principal investigator at the Karolinska Institutet in Sweden and one of the researchers who drove this renaming effort, put it plainly: the old name focused attention on the least of many patients' problems. It made the condition sound like a gynecological issue, something to do with fertility or ovarian health. In reality, PMOS is a systemic disorder—a tangle of hormonal and metabolic disturbances that ripple through the entire body. Male hormone levels are often elevated. The brain's signaling to the ovaries goes awry. The body's response to insulin becomes blunted, which is why people with PMOS face significantly higher risks of type 2 diabetes, obesity, fatty liver disease, and cardiovascular disease. There is also an increased risk of depression, anxiety, sleep apnea, and endometrial cancer. The condition begins early in life and persists throughout it.
The new three-part name tries to capture this complexity. "Polyendocrine" acknowledges the multiple hormonal systems involved. "Metabolic" recognizes the lifelong threat of diabetes and heart disease. "Ovarian" keeps the link to the fertility and ovulation problems that remain central to the condition. It is a name that tells a more complete story.
The practical consequences of the old name have been substantial. Women with PCOS were routinely told their symptoms were a fertility problem or a weight problem. Diagnosis took, on average, more than two years. Few were warned about their lifelong metabolic risks. The renaming should change this. It should accelerate diagnosis. It should prompt doctors to screen for metabolic complications earlier. It should help women understand that their condition is not something that ends when they decide they don't want children, but something that will require attention throughout their lives.
There is an important clarification: the diagnostic criteria for PMOS have not changed. If you already have a PCOS diagnosis, it will simply be called PMOS now. No new tests are required. No new hospital appointments need to be scheduled. The condition still has no cure. Treatment still begins with lifestyle change—diet, exercise, weight management—often supported by medications like metformin, hormonal contraceptives, and increasingly, GLP-1 receptor agonists.
But for Stener-Victorin and the researchers who spent more than a decade on this effort, getting the name right is foundational. It is the ground on which better understanding, faster diagnosis, and more comprehensive care can be built. A name, it turns out, is not just a label. It shapes how doctors think about a disease, how patients understand their own bodies, and what kind of help they will seek and receive.
Citações Notáveis
The name 'PCOS' focused attention on a part of the body that, for many patients, is the least of their problems. It implied the condition was solely a gynaecological issue. In reality, it's a complex hormonal and metabolic disorder that begins early in life and lasts a lifetime.— Dr. Elisabet Stener-Victorin, Karolinska Institutet
Getting the name right is the foundation that everything else rests on.— Dr. Elisabet Stener-Victorin
Quer a matéria completa?
Leia o original em The Irish Times ↗
Health & Medicine